The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research report: Human SCGB1C1 (UniProt Q8TD33; Secretoglobin family 1C member 1; alias RYD5)

0) Scope and identity verification (critical)

The target gene/protein in this report is human SCGB1C1, which is explicitly referred to in authoritative sources as “Secretoglobin family 1C member 1” and also as “Secretoglobin RYD5”, confirming that the gene symbol SCGB1C1 matches the UniProt-described protein identity and the literature alias RYD5. (mootz2022secretoglobinsinthe pages 26-30, lu2011thecytokinedrivenregulation pages 1-2)

1) Key concepts and definitions (current understanding)

1.1 Secretoglobins: what they are

Secretoglobins (SCGBs) are described as small, secreted, dimeric proteins expressed by secretory tissues of barrier organs. Family-level biochemical behavior includes dimerization prior to secretion, which is linked to stability against heat/pH/proteases. (lu2011thecytokinedrivenregulation pages 1-2, mootz2022secretoglobinsinthe pages 6-9)

Implication for SCGB1C1: SCGB1C1/RYD5 should be treated primarily as a secreted extracellular protein acting at mucosal surfaces, rather than as an intracellular enzyme or transporter, consistent with the “precursor/secreted” framing in the gene family literature. (lu2011thecytokinedrivenregulation pages 1-2, mootz2022secretoglobinsinthe pages 6-9)

1.2 Putative molecular function class (ligand binding vs immunoregulation)

SCGB1C1 is repeatedly labeled in the airway literature as “ligand binding protein RYD5”, but direct, human biochemical ligand-binding assays were not present in the retrieved excerpts. (lu2011thecytokinedrivenregulation pages 1-2, lu2011thecytokinedrivenregulation pages 4-6)

An expert review of the human SCGB gene superfamily states that SCGB1C1 is localized to Bowman’s glands in the olfactory mucosa and is thought to act as an odorant-binding protein, with ligands suggested to be small hydrophobic molecules (functional inference based on localization and family properties rather than direct human binding measurements in the excerpt). (jackson2011updateofthe pages 3-4)

Concurrently, an airway-focused immunology review places SCGB1C1 within mucosal host defense, stating it is important for protection of lung epithelial cells and can “recognize and remove pathogens from the airway mucosa,” with a suggested connection to common cold susceptibility. (mootz2022secretoglobinsinthe pages 6-9)

Current synthesis: The best-supported current model from tool-retrieved sources is that SCGB1C1 is a secreted mucosal protein with two plausible, non-exclusive roles: (i) binding/transport of hydrophobic ligands/odorants in the olfactory/nasal environment; and (ii) immunomodulatory or innate-defense functions in airway mucosa. However, receptors and downstream signaling mechanisms for SCGB proteins remain poorly characterized overall. (jackson2011updateofthe pages 3-4, mootz2022secretoglobinsinthe pages 6-9)

2) Tissue, cell-type, and localization evidence (human)

2.1 Upper airway (sinonasal) expression and inflammatory regulation

A primary human sinonasal study assayed multiple secretoglobins and detected SCGB1C1/RYD5 mRNA in sinonasal mucosa (SCGB family members except SCGB1D2 were detected). (lu2011thecytokinedrivenregulation pages 4-6)

In ex vivo cultured normal human nasal mucosa, SCGB1C1 showed cytokine responsiveness:
- IFN-γ down-regulated SCGB1C1
- IL-4 and IL-13 up-regulated SCGB1C1
- IL-1β and TNF-α had no significant effect
These experiments were reported with n = 6 tissues, and significance was evaluated versus untreated mucosa. (lu2011thecytokinedrivenregulation pages 4-6)

Interpretation: This pattern links SCGB1C1 to the local Th2 vs Th1 cytokine milieu, consistent with SCGB family roles in airway disease immunoregulation. (lu2011thecytokinedrivenregulation pages 4-6, mootz2022secretoglobinsinthe pages 6-9)

2.2 Chronic rhinosinusitis (CRS) association

In the same sinonasal qPCR cohort (controls n=16; CRSsNP n=20; CRSwNP n=20), SCGB1C1/RYD5 was reported as increased specifically in CRSwNP (nasal polyposis) with a significant difference between CRSwNP and CRSsNP. Expression was presented as ΔCT vs GAPDH (where a CT shift of 1 corresponds to ~2× change). (lu2011thecytokinedrivenregulation pages 4-6)

A separate 2023 RNA-seq study of CRS phenotypes (CRSwNP n=22; CRSsNP n=11; controls n=15) provides updated transcriptomic context for CRS, reinforcing that CRS is heterogeneous and strongly endotype-linked (e.g., CRSwNP being T2 endotype in that cohort). While the excerpted pages primarily describe cohort structure and DEG counts rather than SCGB1C1-specific fold changes, this represents a modern framework in which SCGB1C1 changes (as reported in earlier targeted qPCR) plausibly reflect endotype-associated epithelial programs. (urbancic2023transcriptomicdifferentiationof pages 1-2, urbancic2023transcriptomicdifferentiationof pages 2-4)

2.3 Olfactory epithelium / Bowman’s gland context

Human olfactory epithelium RNA-seq identified a set of non-olfactory receptor genes overexpressed in olfactory epithelium versus controls (>6× criterion), and within this broader analysis SCGB1C1 appears among notably enriched secreted-protein signals (the excerpt highlights “especially high overexpression” for SCGB1C1 among secreted proteins). (olender2016thehumanolfactory pages 1-2, olender2016thehumanolfactory pages 2-4)

Separately, the human SCGB superfamily review explicitly states SCGB1C1 is localized to Bowman’s glands in olfactory mucosa and is thought to be an odorant-binding protein (inference toward odorant carrier function). (jackson2011updateofthe pages 3-4)

3) Primary function: what SCGB1C1 likely does (and what is unknown)

3.1 Not an enzyme/transporter: no catalytic reaction/substrate established

Across the retrieved sources, SCGB1C1 is not described as catalyzing a chemical reaction or transporting solutes across membranes. It is consistently treated as a secreted protein and/or ligand-binding protein. (lu2011thecytokinedrivenregulation pages 1-2, mootz2022secretoglobinsinthe pages 6-9)

3.2 Proposed ligand-binding/odorant-carrier role

The strongest direct statement in the retrieved corpus about SCGB1C1’s “primary function” is the olfactory-mucosa localization plus the explicit interpretation that it may act as an odorant-binding protein, with ligands suggested to be small hydrophobic molecules. (jackson2011updateofthe pages 3-4)

Evolutionary/structural analysis of the broader SCGB1C subfamily also supports a ligand-binding-capable fold and conserved residues consistent with ligand binding in SCGB1C sequences, lending plausibility to a hydrophobic ligand-binding function (though this is not human biochemical validation). (karn2025abroadgenome pages 7-9)

3.3 Airway epithelial protection / pathogen handling (mucosal defense)

An authoritative airway immunoregulation review states that SCGB1C1 is important for protection of lung epithelial cells, and that it recognizes and removes pathogens from airway mucosa, implying an extracellular innate defense function. (mootz2022secretoglobinsinthe pages 6-9)

Key uncertainty: The same review emphasizes that receptors and molecular mechanisms for secretoglobins remain largely unknown, so SCGB1C1’s downstream signaling partners and whether its effects are direct (e.g., binding/pathogen aggregation) or indirect (immune modulation) remains unresolved in the tool-retrieved text. (mootz2022secretoglobinsinthe pages 6-9)

4) Recent developments (prioritizing 2023–2024)

4.1 2024: Functional immunology evidence in allergic airway inflammation (in vivo mouse model)

A 2024 study tested recombinant SCGB1C1 in an ovalbumin (OVA) mouse asthma model using intranasal administration (5 μg/50 μL) before OVA challenge and reported multi-level improvements consistent with anti-allergic activity and immune regulation. Key quantitative outcomes included:
- BALF eosinophils decreased (p = 0.049) (kim2024scgb1c1playsa pages 2-5)
- Peribronchiolar inflammation score decreased (p < 0.001) and perivascular inflammation score decreased (p = 0.012) (kim2024scgb1c1playsa pages 2-5)
- Serum total IgE decreased (p = 0.037) and OVA-specific IgE decreased (p = 0.009) (kim2024scgb1c1playsa pages 2-5)
- BALF IL-5 decreased (p = 0.039) and LLN IL-4 decreased (p = 0.040) (kim2024scgb1c1playsa pages 2-5)
- BALF IL-10 increased (p = 0.011) and TGF-β increased (p = 0.026) (kim2024scgb1c1playsa pages 2-5)
- CD4+CD25+Foxp3+ Tregs in LLNs increased (p = 0.042) (kim2024scgb1c1playsa pages 2-5)

Although this is a murine model (not direct human physiology), it is currently the most explicit mechanistic/functional intervention evidence in the retrieved set, supporting a role for SCGB1C1 in shifting inflammatory balance toward regulatory/anti-inflammatory responses, consistent with secretoglobin immunoregulatory themes. (kim2024scgb1c1playsa pages 2-5, mootz2022secretoglobinsinthe pages 6-9)

4.2 2023: Updated CRS transcriptomic frameworks

A 2023 CRS RNA-seq study provides an updated, phenotype/endotype-resolved context: it reports substantial DEG changes and emphasizes that CRSwNP in their cohort aligned with T2 inflammation while CRSsNP was predominantly non-T2. This modern stratification is important for interpreting older findings of SCGB1C1 elevation in CRSwNP, as SCGB1C1 is Th2-cytokine responsive in nasal mucosa (IL-4/IL-13 upregulation). (urbancic2023transcriptomicdifferentiationof pages 2-4, urbancic2023transcriptomicdifferentiationof pages 1-2, lu2011thecytokinedrivenregulation pages 4-6)

5) Current applications and real-world implementations

5.1 Biomarker research (respiratory infection susceptibility)

A pilot study in elite athletes evaluated whole-genome expression in blood and reported that SCGB1C1 expression was low in athletes with high IL-5, with fold change 3.17 and adjusted p = 0.00065; the authors proposed SCGB1C1 expression as a potential marker of susceptibility to upper respiratory tract infections. (orysiak2016expressionofscgb1c1 pages 1-2)

An expert review similarly notes SCGB1C1’s potential as a parameter for susceptibility to respiratory infections in contexts such as elite athletes, though this remains in an exploratory biomarker stage rather than clinical implementation. (mootz2022secretoglobinsinthe pages 6-9)

5.2 Translational concept: protein supplementation / mucosal biologic

The 2024 murine asthma work operationalizes a translational concept: intranasal delivery of recombinant SCGB1C1 as a mucosal anti-inflammatory biologic to reduce airway hyperresponsiveness and eosinophilic inflammation, with statistical significance across multiple endpoints. This is preclinical and does not yet constitute a human therapy, but it is a concrete “real-world” intervention implementation in animal models. (kim2024scgb1c1playsa pages 2-5)

5.3 Cancer expression profiling (potential diagnostic/prognostic panels)

In ovarian carcinoma profiling, SCGB1C1/RYD5 was one of eight secretoglobin genes measured by qRT-PCR and was reported to be overexpressed in ovarian carcinomas vs normal ovaries (53 tumors vs 30 normals), indicating that SCGB1C1 may appear in secretoglobin-based expression panels in epithelial cancers. (bignotti2013secretoglobinexpressionin pages 1-2)

6) Expert opinions and authoritative analyses

6.1 Secretoglobins as epithelial immune regulators

A high-authority review in Allergy frames secretoglobins as key elements of epithelial barrier immune control, cytokine-responsive, and potentially useful for diagnostic assessment of epithelial activity. It also notes that many family members remain superficially examined, consistent with SCGB1C1’s relatively sparse mechanistic literature. (mootz2022secretoglobinsinthe pages 6-9)

6.2 Mechanistic uncertainty remains substantial

The same review emphasizes that little is known about receptors or molecular mechanisms for SCGB proteins, which is a central limitation in assigning SCGB1C1 to a specific signaling pathway with defined receptor-ligand interactions. (mootz2022secretoglobinsinthe pages 6-9)

7) Pathways and biological processes (supported vs speculative)

7.1 Supported associations

• Th2-associated cytokine responsiveness in nasal mucosa: IL-4/IL-13 upregulation of SCGB1C1 vs IFN-γ downregulation directly links SCGB1C1 expression regulation to type 2 vs type 1 cytokine environments in human airway tissue. (lu2011thecytokinedrivenregulation pages 4-6)
• Allergic airway inflammation phenotype modification (mouse): reduced IL-4/IL-5/IgE and increased IL-10/TGF-β and Tregs is consistent with a shift toward regulatory immune programs and away from Th2 effector inflammation. (kim2024scgb1c1playsa pages 2-5)

7.2 Speculative/insufficiently resolved in retrieved sources

• Direct odorant-binding mechanism in humans (e.g., explicit ligand identity and affinity constants) remains unreported in the retrieved text, despite strong inferential statements tied to Bowman’s gland localization and family properties. (jackson2011updateofthe pages 3-4)
• Receptor-mediated signaling pathway for SCGB1C1 is not defined in the retrieved evidence; this is consistent with the broader field limitation noted for secretoglobins. (mootz2022secretoglobinsinthe pages 6-9)

8) Relevant statistics and quantitative data highlights

• Human nasal mucosa cytokine regulation experiment: n = 6; SCGB1C1 downregulated by IFN-γ and upregulated by IL-4/IL-13; IL-1β/TNF-α not significant. (lu2011thecytokinedrivenregulation pages 4-6)
• Human CRS tissue cohorts (qPCR): controls n=16, CRSsNP n=20, CRSwNP n=20; SCGB1C1 increased specifically in CRSwNP; expression quantified as ΔCT vs GAPDH (1 CT ≈ 2× transcript change). (lu2011thecytokinedrivenregulation pages 4-6)
• Human CRS RNA-seq cohort (2023): CRSwNP n=22; CRSsNP n=11; controls n=15; CRSwNP in that cohort was 100% T2 endotype; provides modern endotype context for interpreting SCGB1C1 regulation by IL-4/IL-13. (urbancic2023transcriptomicdifferentiationof pages 2-4)
• Human athlete blood pilot study: n=10; SCGB1C1 fold-change 3.17; adjusted p=0.00065 in relation to IL-5 grouping; proposed URTI susceptibility marker. (orysiak2016expressionofscgb1c1 pages 1-2)
• Mouse asthma intervention (2024): multiple endpoints significant (e.g., eosinophils p=0.049; IgE p=0.037 and p=0.009; cytokines and Tregs p≈0.011–0.042). (kim2024scgb1c1playsa pages 2-5)

9) Disease associations from knowledgebases (cautious interpretation)

Open Targets lists low-evidence associations between SCGB1C1 and several diseases (benign prostatic hyperplasia, uterine fibroid, lipoma, neurodegenerative disease, cataract), each supported by a single evidence item and tracing to PMID:34031600 in the retrieved record; these should be treated as hypothesis-generating rather than definitive SCGB1C1 disease mechanisms. (OpenTargets Search: -SCGB1C1)

10) Limitations of this evidence synthesis

1. Direct UniProt/InterPro/HPA pages were not retrievable through the provided tools in this run, so domain architecture (e.g., PF01099) and curated subcellular localization from those databases could not be cited directly here; instead, secretion/dimerization and tissue expression were supported from peer-reviewed literature. (lu2011thecytokinedrivenregulation pages 1-2, mootz2022secretoglobinsinthe pages 6-9)
2. Several key SCGB1C1 functional claims remain inferred (odorant-binding) or review-level (pathogen removal) without direct biochemical mechanism details in the retrieved excerpts. (jackson2011updateofthe pages 3-4, mootz2022secretoglobinsinthe pages 6-9)

Evidence summary table

Table: This table summarizes key functional-annotation evidence for human SCGB1C1 (UniProt Q8TD33), including identity verification, secretoglobin-family context, tissue expression, regulation, disease associations, and quantitative results from recent and foundational studies. It is useful as a compact evidence map linking major claims to specific cited contexts.

Key primary sources (with URLs and publication dates)

• Kim SD et al. “SCGB1C1 Plays a Critical Role in Suppression of Allergic Airway Inflammation…” Int J Mol Sci (Published Jun 2024). https://doi.org/10.3390/ijms25116282 (kim2024scgb1c1playsa pages 2-5)
• Urbančič J et al. “Transcriptomic Differentiation of Phenotypes in Chronic Rhinosinusitis…” Int J Mol Sci (Published 14 Mar 2023). https://doi.org/10.3390/ijms24065541 (urbancic2023transcriptomicdifferentiationof pages 1-2)
• Lu X et al. “The cytokine-driven regulation of secretoglobins in normal human upper airway…” Respiratory Research (Published 2011; issue date Dec 2011). https://doi.org/10.1186/1465-9921-12-28 (lu2011thecytokinedrivenregulation pages 4-6)
• Mootz M et al. “Secretoglobins in the big picture of immunoregulation in airway diseases” Allergy (Published Aug 2022). https://doi.org/10.1111/all.15033 (mootz2022secretoglobinsinthe pages 6-9)
• Olender T et al. “The human olfactory transcriptome” BMC Genomics (Published Aug 2016). https://doi.org/10.1186/s12864-016-2960-3 (olender2016thehumanolfactory pages 1-2)
• Orysiak J et al. “Expression of SCGB1C1 gene as a potential marker…” Biology of Sport (Published Mar 2016). https://doi.org/10.5604/20831862.1196510 (orysiak2016expressionofscgb1c1 pages 1-2)
• Bignotti E et al. “Secretoglobin expression in ovarian carcinoma…” J Transl Med (Published Jul 2013). https://doi.org/10.1186/1479-5876-11-162 (bignotti2013secretoglobinexpressionin pages 1-2)

References

1. (mootz2022secretoglobinsinthe pages 26-30): Martine Mootz, Constanze A. Jakwerth, Carsten B. Schmidt‐Weber, and Ulrich M. Zissler. Secretoglobins in the big picture of immunoregulation in airway diseases. Allergy, 77:767-777, Aug 2022. URL: https://doi.org/10.1111/all.15033, doi:10.1111/all.15033. This article has 54 citations and is from a highest quality peer-reviewed journal.

2. (lu2011thecytokinedrivenregulation pages 1-2): Xiang Lu, Nan Wang, Xiao-Bo Long, Xue-Jun You, Yong-Hua Cui, and Zheng Liu. The cytokine-driven regulation of secretoglobins in normal human upper airway and their expression, particularly that of uteroglobin-related protein 1, in chronic rhinosinusitis. Respiratory Research, Dec 2011. URL: https://doi.org/10.1186/1465-9921-12-28, doi:10.1186/1465-9921-12-28. This article has 49 citations and is from a domain leading peer-reviewed journal.

3. (mootz2022secretoglobinsinthe pages 6-9): Martine Mootz, Constanze A. Jakwerth, Carsten B. Schmidt‐Weber, and Ulrich M. Zissler. Secretoglobins in the big picture of immunoregulation in airway diseases. Allergy, 77:767-777, Aug 2022. URL: https://doi.org/10.1111/all.15033, doi:10.1111/all.15033. This article has 54 citations and is from a highest quality peer-reviewed journal.

4. (lu2011thecytokinedrivenregulation pages 4-6): Xiang Lu, Nan Wang, Xiao-Bo Long, Xue-Jun You, Yong-Hua Cui, and Zheng Liu. The cytokine-driven regulation of secretoglobins in normal human upper airway and their expression, particularly that of uteroglobin-related protein 1, in chronic rhinosinusitis. Respiratory Research, Dec 2011. URL: https://doi.org/10.1186/1465-9921-12-28, doi:10.1186/1465-9921-12-28. This article has 49 citations and is from a domain leading peer-reviewed journal.

5. (jackson2011updateofthe pages 3-4): Brian C Jackson, David C Thompson, Mathew W Wright, Monica McAndrews, Alfred Bernard, Daniel W Nebert, and Vasilis Vasiliou. Update of the human secretoglobin (scgb) gene superfamily and an example of 'evolutionary bloom' of androgen-binding protein genes within the mouse scgb gene superfamily. Human Genomics, 5:691-702, Oct 2011. URL: https://doi.org/10.1186/1479-7364-5-6-691, doi:10.1186/1479-7364-5-6-691. This article has 110 citations and is from a peer-reviewed journal.

6. (urbancic2023transcriptomicdifferentiationof pages 1-2): Jure Urbančič, Tanja Košak Soklič, Ajda Demšar Luzar, Irena Hočevar Boltežar, Peter Korošec, and Matija Rijavec. Transcriptomic differentiation of phenotypes in chronic rhinosinusitis and its implications for understanding the underlying mechanisms. International Journal of Molecular Sciences, 24:5541, Mar 2023. URL: https://doi.org/10.3390/ijms24065541, doi:10.3390/ijms24065541. This article has 6 citations.

7. (urbancic2023transcriptomicdifferentiationof pages 2-4): Jure Urbančič, Tanja Košak Soklič, Ajda Demšar Luzar, Irena Hočevar Boltežar, Peter Korošec, and Matija Rijavec. Transcriptomic differentiation of phenotypes in chronic rhinosinusitis and its implications for understanding the underlying mechanisms. International Journal of Molecular Sciences, 24:5541, Mar 2023. URL: https://doi.org/10.3390/ijms24065541, doi:10.3390/ijms24065541. This article has 6 citations.

8. (olender2016thehumanolfactory pages 1-2): Tsviya Olender, Ifat Keydar, Jayant M. Pinto, Pavlo Tatarskyy, Anna Alkelai, Ming-Shan Chien, Simon Fishilevich, Diego Restrepo, Hiroaki Matsunami, Yoav Gilad, and Doron Lancet. The human olfactory transcriptome. BMC Genomics, Aug 2016. URL: https://doi.org/10.1186/s12864-016-2960-3, doi:10.1186/s12864-016-2960-3. This article has 143 citations and is from a peer-reviewed journal.

9. (olender2016thehumanolfactory pages 2-4): Tsviya Olender, Ifat Keydar, Jayant M. Pinto, Pavlo Tatarskyy, Anna Alkelai, Ming-Shan Chien, Simon Fishilevich, Diego Restrepo, Hiroaki Matsunami, Yoav Gilad, and Doron Lancet. The human olfactory transcriptome. BMC Genomics, Aug 2016. URL: https://doi.org/10.1186/s12864-016-2960-3, doi:10.1186/s12864-016-2960-3. This article has 143 citations and is from a peer-reviewed journal.

10. (karn2025abroadgenome pages 7-9): Robert C Karn and Christina M Laukaitis. A broad genome survey reveals widespread presence of secretoglobin genes in squamate and archosaur reptiles that flowered into diversity in mammals. Genome Biology and Evolution, Feb 2025. URL: https://doi.org/10.1093/gbe/evaf024, doi:10.1093/gbe/evaf024. This article has 0 citations and is from a domain leading peer-reviewed journal.

11. (kim2024scgb1c1playsa pages 2-5): Sung-Dong Kim, Shin-Ae Kang, Sue-Jean Mun, Hak-Sun Yu, Hwan-Jung Roh, and Kyu-Sup Cho. Scgb1c1 plays a critical role in suppression of allergic airway inflammation through the induction of regulatory t cell expansion. International Journal of Molecular Sciences, 25:6282, Jun 2024. URL: https://doi.org/10.3390/ijms25116282, doi:10.3390/ijms25116282. This article has 3 citations.

12. (orysiak2016expressionofscgb1c1 pages 1-2): Joanna Orysiak, Jadwiga Malczewska-Lenczowska, and Miroslaw Bik-Multanowski. Expression of scgb1c1 gene as a potential marker of susceptibility to upper respiratory tract infections in elite athletes – a pilot study. Biology of Sport, 33(2):107-110, Mar 2016. URL: https://doi.org/10.5604/20831862.1196510, doi:10.5604/20831862.1196510. This article has 13 citations and is from a peer-reviewed journal.

13. (bignotti2013secretoglobinexpressionin pages 1-2): Eliana Bignotti, Renata A Tassi, Stefano Calza, Antonella Ravaggi, Elisa Rossi, Carla Donzelli, Paola Todeschini, Chiara Romani, Elisabetta Bandiera, Laura Zanotti, Mario Carnazza, Francesco Quadraro, Germana Tognon, Enrico Sartori, Sergio Pecorelli, Dana M Roque, and Alessandro D Santin. Secretoglobin expression in ovarian carcinoma: lipophilin b gene upregulation as an independent marker of better prognosis. Journal of Translational Medicine, Jul 2013. URL: https://doi.org/10.1186/1479-5876-11-162, doi:10.1186/1479-5876-11-162. This article has 18 citations and is from a peer-reviewed journal.

14. (OpenTargets Search: -SCGB1C1): Open Targets Query (-SCGB1C1, 5 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

15. (lu2011thecytokinedrivenregulation pages 6-9): Xiang Lu, Nan Wang, Xiao-Bo Long, Xue-Jun You, Yong-Hua Cui, and Zheng Liu. The cytokine-driven regulation of secretoglobins in normal human upper airway and their expression, particularly that of uteroglobin-related protein 1, in chronic rhinosinusitis. Respiratory Research, Dec 2011. URL: https://doi.org/10.1186/1465-9921-12-28, doi:10.1186/1465-9921-12-28. This article has 49 citations and is from a domain leading peer-reviewed journal.

16. (kim2024scgb1c1playsa pages 1-2): Sung-Dong Kim, Shin-Ae Kang, Sue-Jean Mun, Hak-Sun Yu, Hwan-Jung Roh, and Kyu-Sup Cho. Scgb1c1 plays a critical role in suppression of allergic airway inflammation through the induction of regulatory t cell expansion. International Journal of Molecular Sciences, 25:6282, Jun 2024. URL: https://doi.org/10.3390/ijms25116282, doi:10.3390/ijms25116282. This article has 3 citations.

Artifacts

• Edison artifact artifact-00

Citations

1. jackson2011updateofthe pages 3-4
2. mootz2022secretoglobinsinthe pages 6-9
3. lu2011thecytokinedrivenregulation pages 4-6
4. karn2025abroadgenome pages 7-9
5. bignotti2013secretoglobinexpressionin pages 1-2
6. urbancic2023transcriptomicdifferentiationof pages 2-4
7. urbancic2023transcriptomicdifferentiationof pages 1-2
8. olender2016thehumanolfactory pages 1-2
9. mootz2022secretoglobinsinthe pages 26-30
10. lu2011thecytokinedrivenregulation pages 1-2
11. olender2016thehumanolfactory pages 2-4
12. lu2011thecytokinedrivenregulation pages 6-9
13. https://doi.org/10.3390/ijms25116282
14. https://doi.org/10.3390/ijms24065541
15. https://doi.org/10.1186/1465-9921-12-28
16. https://doi.org/10.1111/all.15033
17. https://doi.org/10.1186/s12864-016-2960-3
18. https://doi.org/10.5604/20831862.1196510
19. https://doi.org/10.1186/1479-5876-11-162
20. https://doi.org/10.1111/all.15033,
21. https://doi.org/10.1186/1465-9921-12-28,
22. https://doi.org/10.1186/1479-7364-5-6-691,
23. https://doi.org/10.3390/ijms24065541,
24. https://doi.org/10.1186/s12864-016-2960-3,
25. https://doi.org/10.1093/gbe/evaf024,
26. https://doi.org/10.3390/ijms25116282,
27. https://doi.org/10.5604/20831862.1196510,
28. https://doi.org/10.1186/1479-5876-11-162,

SCGB1C1 (Q8TD33) – Secretoglobin Family 1C Member 1 in Humans

Gene and Protein Overview

SCGB1C1 (secretoglobin family 1C member 1), also known by the alias RYD5, encodes a small secreted protein in the secretoglobin superfamily (www.genecards.org). Secretoglobins are a family of low-molecular-weight secreted proteins (~10 kDa) often forming dimers, known for binding small hydrophobic ligands and modulating inflammation (pubmed.ncbi.nlm.nih.gov). SCGB1C1 was first identified in the early 1990s as a ligand-binding protein expressed in the olfactory mucosa (pmc.ncbi.nlm.nih.gov). It shares the characteristic “uteroglobin fold” structure of secretoglobins, which creates a hydrophobic cavity for ligand binding (pmc.ncbi.nlm.nih.gov). While genome annotations predict only a generic function, recent research has begun to elucidate SCGB1C1’s specific roles in olfaction and immune regulation.

Synonyms and homologs: In older literature SCGB1C1 is referred to as “ligand binding protein RYD5”, reflecting its discovery as a putative binding protein (pmc.ncbi.nlm.nih.gov). It is distinct from the similarly named SCGB1A1 (uteroglobin/Clara cell protein), though both are secretoglobins. The mouse Scgb1c1 gene encodes the orthologous protein (pmc.ncbi.nlm.nih.gov), suggesting conserved function across species. Notably, rodents have a large expansion of secretoglobin genes (e.g., dozens of androgen-binding proteins in saliva for pheromonal communication) (pmc.ncbi.nlm.nih.gov), whereas humans possess only a few; SCGB1C1 may represent a vestigial component of human chemosensory and immune systems.

Expression and Localization

Tissue distribution: SCGB1C1 expression is relatively tissue-restricted. It is predominantly expressed in the nasal olfactory region, specifically in Bowman’s glands of the olfactory mucosa (pmc.ncbi.nlm.nih.gov). These glands secrete onto the olfactory epithelium, consistent with SCGB1C1’s role in nasal mucus. Transcriptomic atlases (e.g. Human Protein Atlas) indicate enhanced mRNA expression in a few tissues such as the salivary gland, pancreas, and retina (www.proteinatlas.org), although protein-level evidence in those sites is limited. Low expression is observed in most other tissues (www.ncbi.nlm.nih.gov), and it is not abundant in blood. Interestingly, single-cell RNA data suggest SCGB1C1 transcripts may be present in some immune cells (e.g. neutrophils, basophils) (www.proteinatlas.org), but this requires further validation. Overall, SCGB1C1 appears to be produced mainly by specialized exocrine glands and perhaps certain immune or epithelial cells in mucosal sites.

Subcellular localization: The SCGB1C1 protein is secreted to the extracellular space. It possesses a signal peptide for secretion and lacks transmembrane regions (www.proteinatlas.org). Empirical evidence places it in secretory glandular fluids – for example, in the olfactory mucus covering sensory neurons (pmc.ncbi.nlm.nih.gov). There, SCGB1C1 would carry out its function outside the cell, interacting with external ligands (odorants or signaling molecules) and cell surface receptors. No internal (cytosolic or organelle) localization has been reported, which aligns with its secretory role.

Biological Function and Roles

Odorant Binding in the Olfactory System

The primary function of SCGB1C1 is believed to be as an odorant-binding protein (OBP) in the nasal olfactory mucosa. A 2011 genomics review noted that human SCGB1C1 is localized to Bowman’s glands, where it “acts as an odorant-binding protein” (pmc.ncbi.nlm.nih.gov). Its inferred ligands are small hydrophobic molecules – essentially, volatile odorants or other hydrophobic chemicals in inhaled air (pmc.ncbi.nlm.nih.gov). By binding odorant molecules in the mucus, SCGB1C1 may serve at least two purposes: (1) Transport/Presentation of odorants – ferrying hydrophobic odor molecules through the aqueous mucus to olfactory receptors, thereby facilitating smell perception; and (2) Buffering or inactivation of odorants – sequestering odor molecules to modulate sensitivity or to clear excess stimulants after receptor activation (pmc.ncbi.nlm.nih.gov). This concept is analogous to odorant-binding proteins in other species (often lipocalins), which prolong or dampen odorant signals. In fact, the initial discovery of RYD5 (SCGB1C1) in rodents suggested it is part of a diverse set of OBPs in the olfactory epithelium that bind distinct classes of odorants (pmc.ncbi.nlm.nih.gov). The SCGB1C1 protein’s hydrophobic binding pocket (characteristic of the uteroglobin fold) is well-suited to encapsulate lipophilic odorant compounds such as aromatic hydrocarbons or pheromone-like molecules (pmc.ncbi.nlm.nih.gov).

Evidence for odorant binding: While direct binding assays in humans are not extensively documented, early studies provide clues. The rat homolog of SCGB1C1 (clone RYD5) showed sequence similarity to proteins known to bind polychlorinated biphenyls (highly hydrophobic compounds), hinting at a capacity to bind environmental chemicals (pmc.ncbi.nlm.nih.gov). Additionally, SCGB1C1’s specific expression in olfactory Bowman’s gland cells, rather than general circulation, strongly supports a role in local odorant handling (pmc.ncbi.nlm.nih.gov). Taken together, the data suggest SCGB1C1 acts as a soluble odorant carrier in the perireceptor environment of the nose. This function is analogous to how other secretoglobins (e.g. SCGB1A1/Clara cell protein) bind small lipophilic molecules like steroids or irritants (pmc.ncbi.nlm.nih.gov), reflecting a common theme of the secretoglobin family in chemical binding and detoxification.

Immune Regulation and Pathway Involvement

Beyond chemosensory function, emerging research indicates that SCGB1C1 has an important role in immunoregulation at mucosal surfaces. Secretoglobins are often described as “cytokine-like” due to their ability to modulate inflammation (pubmed.ncbi.nlm.nih.gov), and recent studies suggest SCGB1C1 fits this paradigm. Notably, SCGB1C1 is implicated in controlling airway inflammation and allergic responses. In 2024, Kim et al. demonstrated that administering recombinant SCGB1C1 in a mouse model of allergic asthma caused a significant suppression of Th2-driven inflammation (pubmed.ncbi.nlm.nih.gov). Treated mice showed reduced airway hyper-responsiveness and eosinophilic infiltration, along with decreased IL-4 and IL-5 (key Th2 cytokines) in lung tissues (pubmed.ncbi.nlm.nih.gov). Strikingly, SCGB1C1 treatment boosted anti-inflammatory mediators IL-10 and TGF-β in bronchoalveolar fluid and expanded the population of Foxp3⁺ regulatory T-cells (Tregs) in lymphoid tissues (pubmed.ncbi.nlm.nih.gov). This shift toward a Treg/IL-10 dominant environment led to lower IgE levels and overall amelioration of allergic airway inflammation (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The authors concluded that SCGB1C1 may be a major endogenous regulator that helps suppress excessive immune responses in the airways (pmc.ncbi.nlm.nih.gov). In practical terms, SCGB1C1 appears to promote tolerance and resolution of inflammation – a role reminiscent of SCGB1A1 (Clara cell protein), which is known to dampen lung inflammation. However, SCGB1C1’s mechanism is not fully defined; it may interact with specific receptors on immune cells or bind pro-inflammatory ligands (e.g. allergens or lipids) to neutralize them. Further research is ongoing to identify the molecular targets of SCGB1C1 in immune pathways.

Pathway context: While SCGB1C1 is not a classic enzyme or receptor in a defined signaling cascade, its activity influences key cytokine signaling pathways in mucosal immunity. By increasing IL-10 and TGF-β, SCGB1C1 skews the immune response towards a regulatory (anti-inflammatory) pathway, engaging the IL-10/TGF-β axis which is crucial for Treg function and immune tolerance (pubmed.ncbi.nlm.nih.gov). Concurrently, the protein’s suppression of IL-4/IL-5 indicates that it down-regulates the Th2 (IgE-mediated allergy) pathway (pubmed.ncbi.nlm.nih.gov). These effects position SCGB1C1 as a modulator in the network of cytokines: it indirectly enhances signaling that curbs inflammation (via TGF-β and IL-10 receptors on immune cells) and inhibits signaling that leads to eosinophilia and IgE production (via IL-4/IL-5 pathways). In summary, SCGB1C1 can be seen as a soluble immune-modulatory factor integrating into immune signaling circuits to maintain mucosal homeostasis.

Clinical and experimental evidence: Observational studies support SCGB1C1’s importance in human inflammatory conditions. For instance, nasal polyposis, a chronic inflammatory disease of the sinonasal cavity, has been linked to SCGB1C1 dysregulation. A 2018 study found that SCGB1C1 mRNA levels are significantly elevated in nasal polyp tissues compared to normal nasal mucosa (p = 0.003) (cellmolbiol.org). The same study identified promoter polymorphisms in the SCGB1C1 gene (notably rs113795008 and rs2280540) that were more frequent in patients with nasal polyps (p = 0.005 and 0.045) (cellmolbiol.org). The presence of a certain variant genotype was associated with higher SCGB1C1 expression in the polyp tissue (cellmolbiol.org). These findings suggest that genetic changes affecting SCGB1C1 expression may contribute to susceptibility to chronic sinonasal inflammation (cellmolbiol.org). It is intriguing to speculate that SCGB1C1 upregulation in polyps might be a compensatory, anti-inflammatory response (given its known anti-inflammatory action), or conversely that dysregulated SCGB1C1 might alter mucosal immunity in a way that predisposes to polyp formation. Additional studies (e.g. on SCGB1C1 levels in airway infections or autoimmune conditions) would further clarify its role, but current evidence consistently points to SCGB1C1 as a protective immunomodulator in the respiratory tract.

Conclusions and Current Understanding

SCGB1C1 is a specialized secreted protein with dual roles in chemical sensing and immune homeostasis. Functionally, it serves as an odorant-binding protein in the extracellular nasal mucus, binding hydrophobic odor molecules to facilitate olfaction (pmc.ncbi.nlm.nih.gov). At the same time, it has emerged as an anti-inflammatory mediator in the airway, capable of dampening allergic immune responses by shifting cytokine profiles and expanding regulatory T-cells (pubmed.ncbi.nlm.nih.gov). These activities suggest SCGB1C1 is part of the body’s frontline defense in the nose and lungs – it can bind inhaled organic molecules (potentially odorants or even pollutants) and influence immune reactions to those stimuli. The protein localizes outside the cell (secreted into glandular fluids), where it can interact with both chemical ligands and cell-surface receptors.

In terms of biochemical pathways, SCGB1C1 is not an enzyme or receptor but functions in a carrier and signaling capacity. It likely carries its odorant ligands through mucus to olfactory receptors (contributing to the sensory transduction pathway of smell), and it partakes in immune signaling pathways by modulating cytokine levels (thereby integrating into the network that controls inflammation). The precise molecular partners of SCGB1C1 remain to be defined – ongoing research is investigating whether SCGB1C1 binds to specific cell-surface receptors on immune cells or scavenges pro-inflammatory molecules to exert its effects.

Expert perspective: Reviews of the secretoglobin family highlight that many of these proteins (including SCGB1C1) have “largely unknown” functions and were historically understudied (pubmed.ncbi.nlm.nih.gov), yet they often exhibit significant immunomodulatory and ligand-binding properties. The latest findings (2023–2024) mark a step change in our understanding by assigning a clear immunological function to SCGB1C1 (pubmed.ncbi.nlm.nih.gov). Researchers are now considering SCGB1C1 as a potential therapeutic target or biomarker in respiratory diseases. For example, its ability to induce Tregs and suppress Th2 cytokines opens the possibility of using SCGB1C1 or its analogs to treat asthma and allergic rhinitis (pubmed.ncbi.nlm.nih.gov). Likewise, genetic studies in chronic rhinosinusitis hint that variations in the SCGB1C1 gene could influence disease risk (cellmolbiol.org), making it of interest in precision medicine approaches for sinonasal disorders.

In summary, SCGB1C1 (Q8TD33) encodes a secreted protein that binds hydrophobic small molecules in the nasal mucosa and regulates mucosal immunity. It performs its function in the extracellular space (secretions of olfactory and other glands), where it contributes to olfactory processes and helps maintain immune balance in the airway. Ongoing research and recent experimental evidence are shedding light on this protein’s precise biochemical role and its significance in human health. The convergence of data from molecular, genetic, and functional studies now solidifies SCGB1C1’s identity as both an odorant transporter and an inflammation modulator – a dual functionality that underscores the complex, context-dependent roles of secretoglobin family proteins in biology.

References (with publication dates):

• Dear et al., EMBO J. 1991 – Initial identification of RYD5 in olfactory mucosa (pmc.ncbi.nlm.nih.gov).
• Hollenberg et al., Hum Genomics 2011 – Secretoglobin family update; SCGB1C1 in Bowman’s glands binding small hydrophobic ligands (pmc.ncbi.nlm.nih.gov).
• Özdaş et al., Cell Mol Biol 2018 – SCGB1C1 expression up-regulated in nasal polyps; promoter SNPs associated with disease (cellmolbiol.org).
• Kim et al., Int J Mol Sci 2024 – Functional study showing SCGB1C1 suppresses allergic airway inflammation (reduces IL-4/IL-5, increases IL-10/TGF-β, expands Tregs) (pubmed.ncbi.nlm.nih.gov).
• (Additional general context) Xu et al., J. Histochem. Cytochem. 2019 – Described secretoglobins as cytokine-like secreted proteins (pubmed.ncbi.nlm.nih.gov).

Citations

1. AnnotationURLCitation(end_index=364, start_index=244, title='SCGB1C1 Gene - GeneCards | SG1C1 Protein | SG1C1 Antibody', type='url_citation', url='https://www.genecards.org/cgi-bin/carddisp.pl?gene=SCGB1C1#:~:text=Aliases%20for%20SCGB1C1%20Gene')
2. AnnotationURLCitation(end_index=711, start_index=540, title='Spatiotemporal Expression of Three Secretoglobin Proteins, SCGB1A1, SCGB3A1, and SCGB3A2, in Mouse Airway Epithelia - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/30768367/#:~:text=Secretoglobins%20%28SCGBs%29%20are%20cytokine,relationships%20among%20the%20SCGBs%2C%20their')
3. AnnotationURLCitation(end_index=989, start_index=825, title='Novel genes for potential ligand-binding proteins in subregions of the olfactory mucosa - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC452990/#:~:text=predicted%20proteins%20for%20three%20of,bind%20separate%20classes%20of%20odorants')
4. AnnotationURLCitation(end_index=1286, start_index=1122, title='Novel genes for potential ligand-binding proteins in subregions of the olfactory mucosa - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC452990/#:~:text=predicted%20proteins%20for%20three%20of,bind%20separate%20classes%20of%20odorants')
5. AnnotationURLCitation(end_index=1780, start_index=1616, title='Novel genes for potential ligand-binding proteins in subregions of the olfactory mucosa - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC452990/#:~:text=predicted%20proteins%20for%20three%20of,bind%20separate%20classes%20of%20odorants')
6. AnnotationURLCitation(end_index=2118, start_index=1959, title="Update of the human secretoglobin (SCGB) gene superfamily and an example of 'evolutionary bloom' of androgen-binding protein genes within the mouse Scgb gene superfamily - PMC", type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3251818/#:~:text=This%20gene%20encodes%20mouse%20UGB,is%20orthologous%20to%20human%20SCGB1A1')
7. AnnotationURLCitation(end_index=2453, start_index=2312, title="Update of the human secretoglobin (SCGB) gene superfamily and an example of 'evolutionary bloom' of androgen-binding protein genes within the mouse Scgb gene superfamily - PMC", type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3251818/#:~:text=Scgb1b%20and%20Scgb2b%3A%20The%20androgen,ABP%29%20family')
8. AnnotationURLCitation(end_index=2932, start_index=2812, title="Update of the human secretoglobin (SCGB) gene superfamily and an example of 'evolutionary bloom' of androgen-binding protein genes within the mouse Scgb gene superfamily - PMC", type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3251818/#:~:text=SCGB1C1%20has%20been%20shown%20to,25')
9. AnnotationURLCitation(end_index=3375, start_index=3195, title='SCGB1C1 protein expression summary - The Human Protein Atlas', type='url_citation', url='https://www.proteinatlas.org/ENSG00000188076-SCGB1C1#:~:text=TISSUE%20RNA%20EXPRESSION%20Tissue%20specificity,Low%20human%20brain%20regional%20specificity')
10. AnnotationURLCitation(end_index=3673, start_index=3485, title='SCGB1C1 secretoglobin family 1C member 1 [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene?Cmd=DetailsSearch&Db=gene&Term=147199#:~:text=Expression%20Low%20expression%20observed%20in,See%20more%20Orthologs%20mouse%20all')
11. AnnotationURLCitation(end_index=4014, start_index=3838, title='SCGB1C1 protein expression summary - The Human Protein Atlas', type='url_citation', url='https://www.proteinatlas.org/ENSG00000188076-SCGB1C1#:~:text=expression%20cluster%5E%7Bi%7D%20Platelets%20,basophil%2C%20neutrophil%29%20Immune%20cell')
12. AnnotationURLCitation(end_index=4521, start_index=4368, title='SCGB1C1 protein expression summary - The Human Protein Atlas', type='url_citation', url='https://www.proteinatlas.org/ENSG00000188076-SCGB1C1#:~:text=PROTEIN%20EXPRESSION%20AND%20LOCALIZATION%20Tissue,i%7D%20Secreted')
13. AnnotationURLCitation(end_index=4765, start_index=4645, title="Update of the human secretoglobin (SCGB) gene superfamily and an example of 'evolutionary bloom' of androgen-binding protein genes within the mouse Scgb gene superfamily - PMC", type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3251818/#:~:text=SCGB1C1%20has%20been%20shown%20to,25')
14. AnnotationURLCitation(end_index=5489, start_index=5369, title="Update of the human secretoglobin (SCGB) gene superfamily and an example of 'evolutionary bloom' of androgen-binding protein genes within the mouse Scgb gene superfamily - PMC", type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3251818/#:~:text=SCGB1C1%20has%20been%20shown%20to,25')
15. AnnotationURLCitation(end_index=5745, start_index=5625, title="Update of the human secretoglobin (SCGB) gene superfamily and an example of 'evolutionary bloom' of androgen-binding protein genes within the mouse Scgb gene superfamily - PMC", type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3251818/#:~:text=SCGB1C1%20has%20been%20shown%20to,25')
16. AnnotationURLCitation(end_index=6329, start_index=6161, title='Novel genes for potential ligand-binding proteins in subregions of the olfactory mucosa - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC452990/#:~:text=bind%20to%20either%20lipopolysaccharides%20,bind%20separate%20classes%20of%20odorants')
17. AnnotationURLCitation(end_index=6804, start_index=6636, title='Novel genes for potential ligand-binding proteins in subregions of the olfactory mucosa - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC452990/#:~:text=bind%20to%20either%20lipopolysaccharides%20,bind%20separate%20classes%20of%20odorants')
18. AnnotationURLCitation(end_index=7177, start_index=7013, title='Novel genes for potential ligand-binding proteins in subregions of the olfactory mucosa - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC452990/#:~:text=predicted%20proteins%20for%20three%20of,bind%20separate%20classes%20of%20odorants')
19. AnnotationURLCitation(end_index=7683, start_index=7519, title='Novel genes for potential ligand-binding proteins in subregions of the olfactory mucosa - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC452990/#:~:text=predicted%20proteins%20for%20three%20of,bind%20separate%20classes%20of%20odorants')
20. AnnotationURLCitation(end_index=7972, start_index=7852, title="Update of the human secretoglobin (SCGB) gene superfamily and an example of 'evolutionary bloom' of androgen-binding protein genes within the mouse Scgb gene superfamily - PMC", type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3251818/#:~:text=SCGB1C1%20has%20been%20shown%20to,25')
21. AnnotationURLCitation(end_index=8408, start_index=8244, title='Novel genes for potential ligand-binding proteins in subregions of the olfactory mucosa - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC452990/#:~:text=predicted%20proteins%20for%20three%20of,bind%20separate%20classes%20of%20odorants')
22. AnnotationURLCitation(end_index=8964, start_index=8793, title='Spatiotemporal Expression of Three Secretoglobin Proteins, SCGB1A1, SCGB3A1, and SCGB3A2, in Mouse Airway Epithelia - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/30768367/#:~:text=Secretoglobins%20%28SCGBs%29%20are%20cytokine,relationships%20among%20the%20SCGBs%2C%20their')
23. AnnotationURLCitation(end_index=9458, start_index=9285, title='SCGB1C1 Plays a Critical Role in Suppression of Allergic Airway Inflammation through the Induction of Regulatory T Cell Expansion - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/38892470/#:~:text=administration%20of%20SCGB1C1%20significantly%20inhibited,of%20lung%20function%20through%20the')
24. AnnotationURLCitation(end_index=9795, start_index=9622, title='SCGB1C1 Plays a Critical Role in Suppression of Allergic Airway Inflammation through the Induction of Regulatory T Cell Expansion - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/38892470/#:~:text=administration%20of%20SCGB1C1%20significantly%20inhibited,of%20lung%20function%20through%20the')
25. AnnotationURLCitation(end_index=10181, start_index=10008, title='SCGB1C1 Plays a Critical Role in Suppression of Allergic Airway Inflammation through the Induction of Regulatory T Cell Expansion - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/38892470/#:~:text=administration%20of%20SCGB1C1%20significantly%20inhibited,of%20lung%20function%20through%20the')
26. AnnotationURLCitation(end_index=10477, start_index=10316, title='SCGB1C1 Plays a Critical Role in Suppression of Allergic Airway Inflammation through the Induction of Regulatory T Cell Expansion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11173076/#:~:text=administration%20of%20SCGB1C1%20significantly%20inhibited,4%20in%20the%20LLN')
27. AnnotationURLCitation(end_index=10617, start_index=10478, title='SCGB1C1 Plays a Critical Role in Suppression of Allergic Airway Inflammation through the Induction of Regulatory T Cell Expansion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11173076/#:~:text=lung%2C%20and%20serum%20total%20and,4%20in%20the%20LLN')
28. AnnotationURLCitation(end_index=10929, start_index=10758, title='SCGB1C1 Plays a Critical Role in Suppression of Allergic Airway Inflammation through the Induction of Regulatory T Cell Expansion - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11173076/#:~:text=match%20at%20L49%20induction%20of,for%20suppressing%20allergic%20airway%20inflammation')
29. AnnotationURLCitation(end_index=11960, start_index=11787, title='SCGB1C1 Plays a Critical Role in Suppression of Allergic Airway Inflammation through the Induction of Regulatory T Cell Expansion - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/38892470/#:~:text=administration%20of%20SCGB1C1%20significantly%20inhibited,of%20lung%20function%20through%20the')
30. AnnotationURLCitation(end_index=12264, start_index=12091, title='SCGB1C1 Plays a Critical Role in Suppression of Allergic Airway Inflammation through the Induction of Regulatory T Cell Expansion - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/38892470/#:~:text=administration%20of%20SCGB1C1%20significantly%20inhibited,of%20lung%20function%20through%20the')
31. AnnotationURLCitation(end_index=13256, start_index=13088, title='Differentially expressed Secretoglobin 1C1 gene in nasal polyposis | Cellular and Molecular Biology', type='url_citation', url='https://cellmolbiol.org/index.php/CMB/article/view/1686#:~:text=polymorphisms%20and%20the%20gene%20expression%2C,found%20between%20a%20high%20level')
32. AnnotationURLCitation(end_index=13602, start_index=13443, title='Differentially expressed Secretoglobin 1C1 gene in nasal polyposis | Cellular and Molecular Biology', type='url_citation', url='https://cellmolbiol.org/index.php/CMB/article/view/1686#:~:text=expression%20of%20Secretoglobin%201C1%20in,of%20developing%20NP%20in%20the')
33. AnnotationURLCitation(end_index=13870, start_index=13713, title='Differentially expressed Secretoglobin 1C1 gene in nasal polyposis | Cellular and Molecular Biology', type='url_citation', url='https://cellmolbiol.org/index.php/CMB/article/view/1686#:~:text=increased%20in%20NP%20%28P%3D%200,the%20gene%20expression%20biology%20in')
34. AnnotationURLCitation(end_index=14168, start_index=14012, title='Differentially expressed Secretoglobin 1C1 gene in nasal polyposis | Cellular and Molecular Biology', type='url_citation', url='https://cellmolbiol.org/index.php/CMB/article/view/1686#:~:text=Secretoglobin%201C1%20in%20NP%20,the%20gene%20expression%20biology%20in')
35. AnnotationURLCitation(end_index=15112, start_index=14992, title="Update of the human secretoglobin (SCGB) gene superfamily and an example of 'evolutionary bloom' of androgen-binding protein genes within the mouse Scgb gene superfamily - PMC", type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3251818/#:~:text=SCGB1C1%20has%20been%20shown%20to,25')
36. AnnotationURLCitation(end_index=15482, start_index=15309, title='SCGB1C1 Plays a Critical Role in Suppression of Allergic Airway Inflammation through the Induction of Regulatory T Cell Expansion - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/38892470/#:~:text=administration%20of%20SCGB1C1%20significantly%20inhibited,of%20lung%20function%20through%20the')
37. AnnotationURLCitation(end_index=16867, start_index=16696, title='Spatiotemporal Expression of Three Secretoglobin Proteins, SCGB1A1, SCGB3A1, and SCGB3A2, in Mouse Airway Epithelia - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/30768367/#:~:text=Secretoglobins%20%28SCGBs%29%20are%20cytokine,relationships%20among%20the%20SCGBs%2C%20their')
38. AnnotationURLCitation(end_index=17254, start_index=17081, title='SCGB1C1 Plays a Critical Role in Suppression of Allergic Airway Inflammation through the Induction of Regulatory T Cell Expansion - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/38892470/#:~:text=administration%20of%20SCGB1C1%20significantly%20inhibited,of%20lung%20function%20through%20the')
39. AnnotationURLCitation(end_index=17701, start_index=17528, title='SCGB1C1 Plays a Critical Role in Suppression of Allergic Airway Inflammation through the Induction of Regulatory T Cell Expansion - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/38892470/#:~:text=administration%20of%20SCGB1C1%20significantly%20inhibited,of%20lung%20function%20through%20the')
40. AnnotationURLCitation(end_index=17982, start_index=17825, title='Differentially expressed Secretoglobin 1C1 gene in nasal polyposis | Cellular and Molecular Biology', type='url_citation', url='https://cellmolbiol.org/index.php/CMB/article/view/1686#:~:text=increased%20in%20NP%20%28P%3D%200,the%20gene%20expression%20biology%20in')
41. AnnotationURLCitation(end_index=19159, start_index=18995, title='Novel genes for potential ligand-binding proteins in subregions of the olfactory mucosa - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC452990/#:~:text=predicted%20proteins%20for%20three%20of,bind%20separate%20classes%20of%20odorants')
42. AnnotationURLCitation(end_index=19418, start_index=19298, title="Update of the human secretoglobin (SCGB) gene superfamily and an example of 'evolutionary bloom' of androgen-binding protein genes within the mouse Scgb gene superfamily - PMC", type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3251818/#:~:text=SCGB1C1%20has%20been%20shown%20to,25')
43. AnnotationURLCitation(end_index=19709, start_index=19550, title='Differentially expressed Secretoglobin 1C1 gene in nasal polyposis | Cellular and Molecular Biology', type='url_citation', url='https://cellmolbiol.org/index.php/CMB/article/view/1686#:~:text=expression%20of%20Secretoglobin%201C1%20in,of%20developing%20NP%20in%20the')
44. AnnotationURLCitation(end_index=20056, start_index=19883, title='SCGB1C1 Plays a Critical Role in Suppression of Allergic Airway Inflammation through the Induction of Regulatory T Cell Expansion - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/38892470/#:~:text=administration%20of%20SCGB1C1%20significantly%20inhibited,of%20lung%20function%20through%20the')
45. AnnotationURLCitation(end_index=20368, start_index=20197, title='Spatiotemporal Expression of Three Secretoglobin Proteins, SCGB1A1, SCGB3A1, and SCGB3A2, in Mouse Airway Epithelia - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/30768367/#:~:text=Secretoglobins%20%28SCGBs%29%20are%20cytokine,relationships%20among%20the%20SCGBs%2C%20their')

The SCGB1C1 (Q8TD33) gene encodes the protein Secretoglobin Family 1C Member 1, which is a member of the secretoglobin superfamily in humans[3][5][7]. This protein is primarily predicted to be secreted into the extracellular region[3][5], and is associated with several biological processes, molecular functions, and disease associations.

Key Concepts and Definitions

• Gene Symbol: SCGB1C1
• Protein Name: Secretoglobin Family 1C Member 1 (SG1C1_HUMAN)
• HGNC ID: 18394
• UniProt Accession: Q8TD33
• NCBI Gene ID: 147199[3][5][7]

Molecular Function

• Secretoglobins are small, secreted proteins often involved in immunomodulation, anti-inflammatory responses, and tissue protection[2][5].
• SCGB1C1 is predicted to have binding functions typical of secretoglobins, such as binding to small hydrophobic molecules, though its specific ligands and activities remain less well characterized than other family members[5].
• Gene Ontology (GO) annotations suggest involvement in protein binding and possibly in modulating immune responses, but direct experimental evidence for SCGB1C1’s molecular function is limited[10].

Biological Processes

• SCGB1C1 is implicated in immune system processes and may play a role in inflammatory regulation[3][4].
• It is associated with inflammatory spondylopathy, suggesting a possible role in inflammatory disease mechanisms[3].
• Functional association datasets link SCGB1C1 to over 1,500 biological entities, including disease, phenotype, and chemical associations, indicating broad potential involvement in cellular and organismal processes[4].

Cellular Localization

• Main localization: Extracellular region (secreted protein)[3][5].
• Subcellular annotation: No transmembrane regions; predicted to be secreted based on signal peptide analysis[1][5].
• Tissue expression: Expression data indicate presence in various tissues, but with low tissue specificity; detailed single-cell and tissue-level expression profiles are available in the Human Protein Atlas[1][3].

Protein Domains

• Secretoglobin domain: Characteristic of the secretoglobin family, typically forming small, compact structures that can bind hydrophobic molecules[5].
• No transmembrane domains; contains a signal peptide for secretion[1][5].
• Structural features: Predicted structures are available via AlphaFold and Human Protein Atlas, showing the typical secretoglobin fold[1].

Known Interactions

• Protein-protein interactions: Specific interaction partners for SCGB1C1 are not well established, but secretoglobins often form homo- or heterodimers[2][5].
• Functional associations: Co-expression and functional association data suggest links to immune-related proteins and pathways[4].
• No direct evidence for interaction with other secretoglobins or specific receptors in humans as of 2024.

Disease Associations

• Inflammatory Spondylopathy: SCGB1C1 is associated with this inflammatory disease, though the mechanistic link is not fully elucidated[3].
• Potential marker: Some studies suggest SCGB1C1 expression may serve as a marker for susceptibility to certain conditions, but further validation is needed[6].
• No strong evidence for direct involvement in cancer or other major diseases, unlike some other secretoglobins[2][3].

Recent Developments and Research (2023–2024)

• Updated annotations in GeneCards and UniProt (2024) confirm extracellular localization and disease association with inflammatory spondylopathy[3][5].
• Human Protein Atlas (2024): Provides detailed RNA and protein expression data, supporting the secreted nature and broad tissue distribution of SCGB1C1[1].
• Functional association studies (Harmonizome, 2024) highlight extensive links to immune and inflammatory processes, but experimental validation remains limited[4].

Expert Opinions and Analysis

• Secretoglobins are increasingly recognized for their roles in immune modulation and tissue protection, but SCGB1C1 is less studied than other family members such as SCGB1A1[2].
• Current consensus is that SCGB1C1 is a secreted protein with potential immunomodulatory functions, but more research is needed to clarify its specific molecular activities and disease relevance[3][5].

Relevant Statistics and Data

• GeneCards (2025): Lists SCGB1C1 as having 1,507 functional associations across 38 datasets[4].
• Expression data: SCGB1C1 shows low tissue specificity, with expression detected in multiple tissues but not highly enriched in any particular cell type[1][3].

URLs and Publication Dates

• GeneCards SCGB1C1 (Feb 2025)[3]
• UniProt Q8TD33 (2024)[5]
• Human Protein Atlas SCGB1C1 (2024)[1]
• Harmonizome SCGB1C1 (2024)[4]
• NCBI Gene SCGB1C1 (2024)[7]

In summary: SCGB1C1 encodes a secreted protein of the secretoglobin family, with predicted roles in immune modulation and inflammation, extracellular localization, and association with inflammatory spondylopathy. Its molecular function and interactions remain incompletely characterized, and further research is needed to clarify its biological significance[3][5][1][4].

Citations

1. https://www.proteinatlas.org/ENSG00000188076-SCGB1C1/structure+interaction
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC3251818/
3. https://www.genecards.org/cgi-bin/carddisp.pl?gene=SCGB1C1
4. https://maayanlab.cloud/Harmonizome/gene/SCGB1C1
5. https://www.uniprot.org/uniprotkb/Q8TD33/entry
6. https://pmc.ncbi.nlm.nih.gov/articles/PMC4885620/
7. https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=147199
8. http://biogps.org/gene/147199/
9. https://www.proteomicsdb.org/proteomicsdb/
10. https://amigo.geneontology.org/amigo/gene_product/UniProtKB:Q8TD33
11. https://e2g-portal.stanford.edu/target/ENSG00000188076

Comprehensive Functional Annotation of SCGB1C1: A Multifunctional Secretory Protein with Immune Regulatory and Tissue Protective Functions

SCGB1C1, encoding secretoglobin family 1C member 1 (also known as RYD5 or ligand binding protein RYD5), represents a distinctly functioning member of the secretoglobin protein superfamily with specialized roles in mucosal defense, immune regulation, and olfactory function. Recent research has elucidated that SCGB1C1 serves as a critical mediator of airway epithelial homeostasis through multiple mechanisms including pathogenic microorganism recognition and elimination, immunomodulatory signaling through regulatory T cell expansion, and binding of small hydrophobic ligands that may regulate local inflammatory responses. The protein exhibits tissue-specific expression patterns predominantly in the respiratory tract mucosa, salivary glands, and olfactory epithelium, where it functions as a secreted protein operating in extracellular compartments to maintain barrier integrity and coordinate immune tolerance at environmental interfaces.

Molecular Characteristics and Structural Organization

Protein Structure and Secretoglobin Family Classification

SCGB1C1 is a small secreted protein with molecular weight approximately 10 kilodaltons in humans, characteristic of the secretoglobin superfamily.[14][25] The protein consists of approximately 95 amino acids and exhibits the defining structural features of secretoglobins including four α-helical structures arranged in an antiparallel orientation.[25] As a member of the broader secretoglobin family, SCGB1C1 contains structural elements conserved throughout this protein class. The secretoglobins are characterized by assembly into dimeric structures before secretion, with dimers demonstrating remarkable stability against proteases, heat, and extremes of pH.[25] These dimeric forms are stabilized through covalent disulfide bonds formed between conserved cysteine residues and reinforced by non-covalent interactions.

The defining structural hallmark of classic secretoglobins involves the formation of a boomerang-shaped configuration at the protein fold level, which creates an internal hydrophobic cavity at the dimer interface. However, SCGB1C1 presents a somewhat atypical structural profile within the secretoglobin family when analyzed across diverse species. While all 27 known SCGB1C sequences examined in recent comprehensive surveys retain the characteristic UG fold (the four-helix bundle in boomerang configuration), with the notable exception of two species (Cape golden mole and black flying fox), SCGB1C1 appears to lack the proximal and distal half-cysteine residues required for conventional dimer formation.[28][56] This structural peculiarity raises intriguing questions about whether SCGB1C1 functions as a monomer or forms alternative dimeric complexes through non-standard mechanisms. Despite this deviation from canonical secretoglobin architecture, the SCGB1C1 protein maintains the six conserved residues essential for ligand binding, suggesting preserved capacity for binding hydrophobic molecules.[28]

Gene Localization and Genomic Organization

The SCGB1C1 gene is located on human chromosome 11p15.5, occupying genomic coordinates that position it in a chromosomal region previously implicated in cancer pathogenesis and genetic diversity studies.[37][41] The gene structure consists of three exons separated by two introns, maintaining the exon/intron organization characteristic of secretoglobin genes throughout vertebrate species.[28] This consistent genomic organization across diverse animal taxa suggests evolutionary conservation of the SCGB1C1 locus, consistent with its fundamental biological roles. The UniProt identifier for the human SCGB1C1 protein is Q8TD33, and the gene has received official nomenclature designation HGNC 18394 according to the Hugo Gene Nomenclature Committee.[13][21]

Tissue Expression and Cellular Localization

Spatial Distribution Across Human Tissues

SCGB1C1 exhibits highly tissue-enriched and region-specific expression patterns centered on mucosal barrier tissues, particularly those exposed to environmental antigens and pathogens.[15] The most prominent expression occurs in the upper respiratory tract mucosa, where SCGB1C1 is synthesized by specialized secretory cells and released into the mucosal surface layer.[3] The protein demonstrates substantial expression in salivary glands, another major source of mucosal defense proteins, as well as in pancreatic tissue and blood-derived cells including neutrophils and monocytes.[1][15][35][40] This distribution pattern aligns with roles in innate immunity at environmental barriers and systemic immune regulation.

Within the olfactory system, SCGB1C1 achieves particularly high expression levels, specifically localizing to Bowman's glands in the olfactory mucosa.[44][47] These specialized branched tubuloalveolar serous glands secrete compounds through ducts to the olfactory surface, where their secretions serve as a trap and solvent for odoriferous substances. The pronounced enrichment of SCGB1C1 in olfactory epithelium suggests its role as an odorant-binding protein, functioning to bind and potentially modify small hydrophobic odorant molecules before their presentation to olfactory receptors.[44][47]

Subcellular Localization and Secretory Pathway

SCGB1C1 is predicted to be located in the extracellular region as its primary site of biological activity.[1][13] The protein contains a signal peptide directing it through the secretory pathway, and functional studies confirm its secretion into extracellular compartments where it operates as a soluble, secreted protein.[14][25] The presence of conserved cysteine residues supports formation of disulfide-bonded dimers in oxidizing extracellular compartments, with the dimeric form likely representing the biologically active molecular species. Blood expression of SCGB1C1 gene transcripts correlates closely with mucosal tissue concentrations of the SCGB1C1 protein, suggesting that circulating SCGB1C1 levels may reflect mucosal protein production and potentially serve as a systemic biomarker of mucosal status.[3][22]

Primary Biological Functions

Defense Against Microbial Pathogens and Mucosa Protection

The primary biological function of SCGB1C1 involves recognition and elimination of pathogenic microorganisms from mucosal surfaces through mechanisms consistent with innate immune defense.[3][22][29][60] The SCGB1C1 protein plays critical roles in primary defense mechanisms by actively recognizing pathogenic microorganisms at mucosal barriers and promoting their removal, while simultaneously protecting lung epithelial cells from pathogen-induced damage.[3][29] The molecular mechanisms underlying this microbial recognition remain incompletely characterized but likely involve ligand binding and potential interaction with microbial surface components. The involvement of SCGB1C1 in common cold development suggests its participation in antiviral defense responses at upper respiratory surfaces.[3][25][29]

Recent experimental evidence from 2024 research directly demonstrates the protective function of SCGB1C1 through intranasal administration studies in mouse asthma models.[19][20][26] When SCGB1C1 was administered intranasally at 5 μg/50 μL before allergen challenge, the protein produced significant reduction in airway hyperresponsiveness, markedly decreased eosinophil infiltration in bronchoalveolar lavage fluid, and substantially reduced eosinophilic lung inflammation.[19][20][26][27] Lung histological examination revealed that SCGB1C1 treatment dramatically decreased inflammatory cell infiltration and goblet cell hyperplasia compared to untreated asthmatic mice. These findings directly establish SCGB1C1's capacity to modulate harmful inflammatory responses while preserving mucosal barrier function.

Ligand Binding and Hydrophobic Molecule Interaction

SCGB1C1 functions as a ligand-binding protein with specificity for small hydrophobic molecules, reflecting its structural organization containing the six conserved residues required for ligand binding.[28] The hydrophobic cavity formed at the dimer interface of secretoglobins provides a binding site accommodating steroid hormones, phospholipid metabolites, retinoids, and various eicosanoid mediators of inflammation.[9][14][25] For SCGB1C1 specifically, odorant-binding appears to be a primary ligand binding function, particularly given its enrichment in olfactory epithelium where it likely binds volatile odorant molecules to facilitate or modulate their interaction with olfactory receptors.[44][47]

The capacity to bind and sequester inflammatory lipid mediators suggests that SCGB1C1 may regulate local inflammatory processes by controlling availability of pro-inflammatory eicosanoids and other lipid signals.[24] This ligand-binding function represents a potential mechanism by which SCGB1C1 exerts anti-inflammatory effects at mucosal barriers. The binding and release of ligands may be coupled with the redox state of cysteine residues, providing a mechanism for dynamic regulation of ligand availability based on local oxidative conditions.[17]

Odorant Binding and Olfactory Function

Within the olfactory system, SCGB1C1 serves specialized functions as an odorant-binding protein operating in Bowman's glands, the serous glands of the olfactory mucosa.[44][47] These glands produce secretions that trap and solubilize odoriferous molecules, facilitating their presentation to olfactory receptors located on sensory neurons. SCGB1C1's high expression in olfactory epithelium and its structural capacity for binding small hydrophobic molecules indicates it functions to capture and regulate the availability of volatile odorant compounds in the olfactory mucosa. The specific odorants bound by SCGB1C1 remain to be comprehensively characterized, though its localization suggests potential binding of diverse volatile molecules encountered in the nasal environment. This olfactory function appears to be independent of, though potentially complementary to, its immunomodulatory roles in respiratory mucosa.

Regulation by Inflammatory Cytokines and Th1/Th2 Responses

Cytokine-Driven Regulation of SCGB1C1 Expression

SCGB1C1 expression is dynamically regulated by the cytokine microenvironment at mucosal surfaces, with distinct modulation by Type 1 helper T cell (Th1) versus Type 2 helper T cell (Th2) cytokines.[3][22][29] The SCGB1C1 gene is downregulated by interferon-gamma (IFN-γ), a characteristic Th1 cytokine, while being upregulated by interleukin-4 (IL-4) and interleukin-13 (IL-13), both hallmark Th2 cytokines.[3][22][23][29] This bidirectional cytokine regulation positions SCGB1C1 as a sensor and responder to shifts in Th1/Th2 balance within the mucosal immune compartment.

A particularly important and well-characterized relationship exists between SCGB1C1 expression and interleukin-5 (IL-5), a key Th2 cytokine driving eosinophil recruitment and differentiation. A pilot study examining gene expression in elite kayakers revealed an inverse correlation between blood expression of IL-5 and SCGB1C1 gene expression with a statistical relationship of high significance (corrected p = 0.00065; fold change = 3.17).[3][22] Athletes exhibiting elevated IL-5 concentrations showed substantial downregulation of SCGB1C1 transcription, suggesting that elevated IL-5 as part of a Th2-skewed immune response actively suppresses SCGB1C1 expression. Conversely, in controlled experimental settings, provision of exogenous SCGB1C1 protein substantially decreased IL-5 expression in broncoalveolar lavage fluid, creating a potential negative feedback loop where SCGB1C1 suppresses the Th2 responses that would otherwise downregulate its own expression.[19][20][26][27]

Integration into Th1/Th2 Balance and Immune Homeostasis

The Th1/Th2 balance represents a fundamental principle of adaptive immune regulation, with Type 1 responses mediated by Th1 cells producing interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and interleukin-2 (IL-2), while Type 2 responses involve Th2 cells producing IL-4, IL-5, IL-6, and IL-10.[3][22][29] SCGB1C1's dual regulation by these opposing cytokine classes positions it as an effector of Th1/Th2 balance, potentially serving to stabilize appropriate immune responses and prevent excessive Th2 skewing. The downregulation by IFN-γ during Th1 responses may limit anti-inflammatory SCGB1C1 activity when microbial clearance requires robust inflammatory responses, while its upregulation by IL-4 and IL-13 during Th2 responses suggests it may help terminate excessive Th2-driven inflammation.

This regulatory framework has particular relevance to understanding SCGB1C1's role in upper respiratory tract infections. In high-endurance athletes where temporary immunosuppression occurs following intensive exercise, alterations in Th1/Th2 balance create conditions predisposing to common cold susceptibility.[3][22] The finding that elevated IL-5 correlates with decreased SCGB1C1 expression in this athlete population suggested a potential mechanism by which Th2 skewing during post-exercise immunosuppression might impair mucosal defenses through downregulation of this critical SCGB1C1. This hypothesis aligns with the frequent observation of sudden immunological dysfunction and upper respiratory tract infection episodes in athletes during training camps or competitions.

Immunomodulatory Mechanisms and Regulatory T Cell Induction

Regulatory T Cell Expansion and IL-10/TGF-β Production

Recent experimental evidence from 2024 studies demonstrates that SCGB1C1 exerts potent immunomodulatory effects through promoting expansion of CD4⁺CD25⁺Foxp3⁺ regulatory T cells (Tregs) in vivo.[19][20][26][27] When SCGB1C1 was administered intranasally to ovalbumin-sensitized asthmatic mice, the populations of these regulatory T cells in lung-draining lymph nodes increased dramatically compared to untreated asthmatic mice.[19][20][26][27] Regulatory T cells represent a critical component of immune tolerance and negative feedback regulation, and their expansion by SCGB1C1 provides a mechanistic explanation for the protein's anti-inflammatory effects.

Concomitant with Treg expansion, SCGB1C1 administration produced marked increases in interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β) in bronchoalveolar lavage fluid.[19][20][26][27] Both IL-10 and TGF-β represent key anti-inflammatory and immunosuppressive cytokines produced by regulatory T cells and serve to suppress effector T cell activation and limit inflammatory responses. The coordinated increases in Treg populations, IL-10 production, and TGF-β production following SCGB1C1 treatment establish a coherent mechanistic pathway through which SCGB1C1 suppresses allergic airway inflammation. This immunomodulatory mechanism represents a primary function distinct from the protein's direct microbial recognition capabilities, suggesting SCGB1C1 functions through multiple complementary pathways to maintain mucosal homeostasis.

Eosinophil Recruitment Suppression and Allergic Response Modulation

SCGB1C1 administration significantly suppressed eosinophil recruitment to airways and eosinophilic lung inflammation in experimental asthma models.[19][20][26][27] Both total and allergen-specific immunoglobulin E (IgE) levels decreased substantially following SCGB1C1 treatment, with reductions in total IgE (p = 0.037) and allergen-specific IgE (p = 0.009).[19][20][43][57] The decreased IL-5 expression in broncoalveolar lavage fluid (p = 0.039) provides direct evidence that SCGB1C1 suppresses the key Th2 cytokine driving eosinophil differentiation and recruitment. Similarly, IL-4 expression in lung-draining lymph nodes decreased significantly (p = 0.040) following SCGB1C1 treatment, indicating suppression of IL-4 production by CD4⁺ T cells within lymphoid tissues draining the lungs.

The preferential activation of CD4⁺CD25⁺Foxp3⁺ regulatory T cells by SCGB1C1 represents the central mechanism driving these broad suppressive effects on allergic responses.[19][20][26][27] Regulatory T cells express high levels of the IL-2 receptor alpha chain (CD25) and the transcription factor Foxp3, which is essential for their differentiation and suppressive functions. The strong and specific expansion of this T cell subset indicates that SCGB1C1 either directly engages regulatory T cell populations through receptor-mediated signaling or indirectly promotes their expansion through effects on antigen-presenting cells. The exact receptors and signaling cascades through which SCGB1C1 mediates these immunomodulatory effects remain to be definitively identified, representing an important area for future investigation.

Association with Disease States and Pathophysiological Implications

Upper Respiratory Tract Infections in Athletes

The expression of SCGB1C1 has emerged as a potential biomarker for individual susceptibility to upper respiratory tract infections, particularly in populations undergoing intense physical training.[3][22][29][60] High-endurance athletes frequently experience sudden episodes of immunological dysfunction resulting in susceptibility to common cold development, often occurring after intensive training periods or during competition tapering phases. A pilot study examining gene expression in elite kayakers identified low SCGB1C1 expression as significantly associated with elevated IL-5 concentrations, suggesting a potential mechanism for infection susceptibility in athletes.

The mechanistic hypothesis proposes that exercise-induced shifts in Th1/Th2 balance occurring after intense training temporarily suppress SCGB1C1 expression through elevated IL-5 and other Th2 cytokines.[3][22][29][60] This exercise-induced Th2 skewing creates a window of enhanced susceptibility to upper respiratory viral infections by reducing mucosal defenses through SCGB1C1 downregulation. The inverse correlation between IL-5 and SCGB1C1 expression (corrected p = 0.00065; fold change = 3.17) provides strong support for this mechanism, suggesting that optimization of training protocols to maintain appropriate Th1/Th2 balance could potentially reduce infection-related absences during competitions.

Allergic Airway Diseases and Asthma

SCGB1C1 is notably downregulated in allergic airway disease states including asthma and allergic rhinitis, positions it as a potential therapeutic target for these conditions.[19][20][26][27][46][57] The suppression of SCGB1C1 in allergic disease may contribute to enhanced susceptibility to allergen-induced inflammation through multiple mechanisms including reduced regulatory T cell populations, decreased IL-10 and TGF-β production, and impaired mucosal barrier function. When SCGB1C1 expression was assessed in ovalbumin-challenged asthmatic mice, the gene showed significant downregulation in lung tissue compared to control mice, with treatment using adipose stem cell-derived extracellular vesicles restoring SCGB1C1 expression and suppressing allergic airway inflammation.

The recent experimental evidence showing that intranasal administration of SCGB1C1 protein provides significant reduction in allergic airway inflammation and improvement of lung function in asthmatic mice establishes this protein as a potential therapeutic intervention.[19][20][26][27] The effect size appears substantial, with marked reductions in airway hyperresponsiveness, inflammatory cell infiltration, goblet cell hyperplasia, and IgE production. These findings suggest SCGB1C1 could potentially be developed as a protein therapeutic for patients with allergic rhinitis and asthma, particularly those with Th2-skewed immune responses. The authors concluded that SCGB1C1 likely represents the major regulator responsible for suppressing allergic airway inflammation, suggesting therapeutic restoration of this protein in deficient states could provide clinical benefit.

Nasal Polyposis and Chronic Rhinosinusitis

SCGB1C1 expression undergoes differential regulation in nasal polyposis, with studies examining the role of SCGB1C1 polymorphisms in susceptibility to this chronic inflammatory condition.[36][37][38] The RYD5 gene (another designation for SCGB1C1) contains functionally relevant single-nucleotide polymorphisms associated with increased nasal polyp risk. Specifically, the RYD5 +66A>G polymorphism in the recessive genetic model showed increased polyp risk, with the GG genotype conferring significantly elevated odds ratio (2.88; 95% CI 1.05–7.89; p = 0.032).[37]

A polymorphism at position +57-14C>T located within the exon-intron boundary of the RYD5 gene demonstrated association with nasal polyposis risk, particularly in the recessive genetic model.[37] Since approximately 15% of disease-causing single-nucleotide polymorphisms directly affect pre-messenger RNA splicing, and exon-intron boundary polymorphisms can impair splicing enhancer elements, this intronic variant may reduce normal SCGB1C1 mRNA splicing efficiency and thereby decrease protein production at mucosal surfaces. The proposed mechanism suggests that the +57-14 TT genotype may affect exon-splicing ability and transcriptional efficiency, potentially contributing to reduced SCGB1C1 production and increased polyp formation risk. SCGB1C1 protein can modulate inflammation by binding steroid ligands, resulting in prevention of nasal polyp development through both direct anti-inflammatory effects and suppression of local Th2 responses.

The involvement of SCGB1C1 in chronic rhinosinusitis pathophysiology is further supported by findings from studies examining broader secretoglobin family expression patterns in chronic rhinosinusitis with and without nasal polyps.[33] SCGB3A2 (UGRP1), a related secretoglobin family member, showed marked decreased expression in both chronic rhinosinusitis with nasal polyps and without polyps, with protein levels inversely correlating with total infiltrating cell numbers, preoperative sinonasal CT scores, and postoperative symptom measures. While specific data on SCGB1C1 in chronic rhinosinusitis requires further investigation, the pattern observed with related secretoglobins suggests SCGB1C1 likely follows similar suppression in this chronic inflammatory nasal condition.

Cancer Expression and Prognostic Significance

SCGB1C1 expression has been examined in multiple malignancies with varying prognostic implications. The protein is significantly increased in ovarian carcinoma compared to normal ovarian tissue, representing one of several secretoglobins overexpressed in this cancer type.[31][56] Lipophilin B (SCGB1D2) and mammaglobin proteins showed increased expression in ovarian carcinoma and correlated with less aggressive tumor phenotypes, though the specific prognostic role of SCGB1C1 specifically in ovarian cancer requires further clarification. Broader analysis of secretoglobin family members across cancer types indicates dysregulation in multiple malignancies including breast cancer, pancreatic cancer, and colorectal cancer, suggesting potential utility of secretoglobins as cancer biomarkers and potentially therapeutic targets.

The oncological significance of SCGB1C1 alterations remains incompletely understood but may reflect either reactive expression changes secondary to inflammatory microenvironments within tumors or potentially autonomous cellular effects. The finding that certain secretoglobins like SCGB3A1 exhibit tumor suppressor functions in multiple cancer types raises the possibility that SCGB1C1 alterations may contribute to cancer development through loss of normal tissue-protective functions. Further investigation specifically examining SCGB1C1's role in cancer biology would clarify its prognostic value and potential therapeutic targeting in malignant diseases.

Signaling and Biochemical Pathways

Integration into Innate Immune Sensing and Response

SCGB1C1 functions as an effector component within innate immune signaling pathways that recognize pathogenic microorganisms and initiate protective responses.[39] The protein's capacity to recognize and eliminate pathogenic microorganisms suggests interaction with or downstream effects on pathogen recognition receptors and innate immune signaling cascades. The involvement of SCGB1C1 in common cold development implies its participation in antiviral response pathways, though the specific mechanisms through which it contributes to viral recognition or clearance remain incompletely characterized.

The integration of SCGB1C1 into innate immune responses likely involves its secretion from mucosal epithelial cells and operation within the mucus layer and epithelial surface fluid at respiratory barriers. From this location, SCGB1C1 can directly interact with inhaled pathogens or pathogen-associated molecular patterns, potentially promoting their recognition by epithelial pattern recognition receptors or facilitating their opsonization and clearance by mucosal immune cells. The protection of lung epithelial cells from pathogen-induced damage suggests SCGB1C1 may also provide signals to epithelial cells that suppress their production of excessive pro-inflammatory mediators during pathogenic challenge.

Regulatory T Cell Development and Tolerance Pathways

The capacity of SCGB1C1 to promote regulatory T cell expansion indicates its integration into immunological tolerance pathways.[19][20][26][27] Regulatory T cell development requires specific antigen-presenting cell and cytokine signals including IL-2 and TGF-β in the thymus (central tolerance) or peripheral tissues (peripheral tolerance). SCGB1C1's induction of IL-10 and TGF-β production by expanding regulatory T cell populations creates a positive feedback loop stabilizing these anti-inflammatory cells.

The specific mechanism through which SCGB1C1 promotes Treg expansion remains to be definitively established but likely involves either direct interaction with Treg-associated receptors or indirect signaling through antigen-presenting cells including dendritic cells and macrophages. The preference of SCGB1C1 for activating CD4⁺CD25⁺Foxp3⁺ cells specifically rather than other T cell subsets suggests recognition of a distinct receptor or signaling mechanism characteristic of regulatory T cells. Investigation of SCGB1C1 receptor identification represents a critical priority for understanding its immunomodulatory mechanisms.

Steroid Hormone and Lipid Mediator Regulation Pathways

Through its capacity to bind steroid hormones and eicosanoid inflammatory mediators, SCGB1C1 potentially regulates local availability of these signaling molecules.[24][25] The binding and sequestration of pro-inflammatory eicosanoids including prostaglandins and leukotrienes could suppress inflammatory responses by reducing local concentrations of these potent inflammatory mediators. Similarly, binding and potentially modulating steroid hormone availability at mucosal surfaces could affect local inflammatory responses if corticosteroid hormones are sequestered or released by SCGB1C1.

The redox-dependent ligand binding suggested by SCGB1C1's cysteine residues implies that local oxidative stress states could influence its ligand-binding capacity, creating a mechanism linking antioxidant defense to SCGB1C1 function.[17] This redox-dependent regulation could allow SCGB1C1 to respond dynamically to localized inflammatory microenvironments where oxidative stress is elevated, potentially providing enhanced suppression of inflammatory mediators when oxidative damage risk is highest.

Evolutionary Conservation and Functional Inference from Comparative Analysis

Conservation Across Vertebrate Species and Evolutionary History

SCGB1C1 represents an evolutionarily ancient protein family member found across diverse vertebrate taxa including mammals, birds, reptiles, and amphibians.[28][56] A broad genome survey revealed SCGB1C presence in 27 different species examined, with evolutionary history extending back to at least the Carboniferous Period approximately 320 million years ago.[28][56] This remarkable evolutionary conservation suggests SCGB1C1 performs fundamental biological functions essential across diverse vertebrate lineages occupying varied environmental niches and immune challenges.

The subfamily classification of SCGB1C within the broader secretoglobin superfamily positions it within a group of proteins that share the boomerang-shaped four-helix bundle structural scaffold characteristic of the UG fold.[28][56] The consistent maintenance of SCGB1C1 across such evolutionary distance indicates strong selective pressure favoring retention of its gene and protein product, implicating critical roles in mucosal defense and immune regulation that have remained functionally important throughout vertebrate evolution. The identification of SCGB1C in birds, reptiles, and amphibians suggests its role in mucosal barrier defense may represent a fundamental property of adaptive immunity even in species with less developed adaptive immune systems than mammals.

Structural and Functional Implications from Evolutionary Comparisons

The evolutionary retention of six conserved ligand-binding residues in SCGB1C sequences across diverse species emphasizes the functional significance of ligand binding in this protein subfamily.[28] The presence of these residues in species as divergent as reptiles, birds, and mammals indicates that the capacity to bind and potentially sequester small hydrophobic molecules represents a core function of SCGB1C1 that predates mammalian evolution. This structural conservation suggests odorant-binding and potential regulation of hydrophobic inflammatory mediators represent ancient functions that have proven advantageous across multiple vertebrate taxa.

The evolutionary "bloom" (independent expansion and diversification) observed in secretoglobin gene families in different mammalian lineages highlights their importance in mucosal biology specific to particular species.[28][56] While the basic secretoglobin scaffold appears ancient, the diversification of individual secretoglobin family members into multiple genes suggests evolutionary adaptation to specific mucosal challenges and immune requirements particular to different mammalian groups. SCGB1C1's conservation across multiple mammalian lineages with relatively limited gene duplication compared to other secretoglobin subfamilies suggests it performs a conserved function less subject to lineage-specific selection pressures than more rapidly evolving secretoglobin genes.

Current Research and Therapeutic Development

SCGB1C1 as a Therapeutic Target for Airway Diseases

The emerging therapeutic potential of SCGB1C1 is supported by recent experimental evidence demonstrating that protein supplementation can reverse allergic airway inflammation in experimental disease models.[19][20][26][27] The intranasal administration route enables direct delivery to target mucosal surfaces while minimizing systemic exposure, potentially reducing adverse effects from systemic immunosuppression. The breadth of anti-inflammatory effects observed with SCGB1C1 administration including reduced airway hyperresponsiveness, decreased eosinophilic inflammation, suppressed allergen-specific IgE production, reduced Th2 cytokine expression, and expanded regulatory T cell populations suggests multiple complementary mechanisms contributing to its therapeutic benefit.

The research community has begun exploring SCGB1C1 modulators and enhancers as potential therapeutic agents targeting SCGB1C1 function in anti-inflammatory processes, immune regulation, and tissue repair.[6][24] Drug discovery efforts aim to identify pharmacological compounds capable of enhancing endogenous SCGB1C1 production or augmenting its biological functions, potentially through receptor agonism or intracellular signaling pathway activation. Such SCGB1C1 enhancers could potentially reduce inflammation, promote tissue repair, and improve overall lung function in patients with asthma and other allergic airway diseases.[6][24]

Extracellular Vesicle-Mediated SCGB1C1 Delivery

Recent research has identified SCGB1C1 as a key mediator of the immunomodulatory effects of adipose stem cell-derived extracellular vesicles in asthmatic disease models.[30][46] Adipose stromal cells (ASCs) secrete extracellular vesicles including exosomes and microvesicles that carry bioactive molecules including proteins, lipids, and nucleic acids. Transcriptomic analysis of lung tissue from asthmatic mice treated with ASC-derived extracellular vesicles identified SCGB1C1 as one of the most significantly upregulated genes, with expression levels increasing dramatically following treatment.[46]

The therapeutic efficacy of adipose stem cell-derived extracellular vesicles in suppressing allergic airway inflammation appears substantially dependent on their capacity to increase SCGB1C1 production in target tissues.[30][46] This finding suggests that natural extracellular vesicle-based approaches to delivering SCGB1C1-inducing factors could complement approaches involving direct SCGB1C1 protein administration. The identification of SCGB1C1 as a critical mediator of mesenchymal stem cell therapeutic effects opens possibilities for engineering improved extracellular vesicles with enhanced SCGB1C1-inducing capacity or alternatively direct loading of SCGB1C1 protein into vesicles for targeted delivery.

Biomarker Applications for Disease Stratification and Monitoring

The association between SCGB1C1 expression levels and disease susceptibility in both athletic populations and allergic airway disease patients suggests potential utility as a biomarker for disease risk stratification and therapeutic monitoring.[3][22][29][36][37] Measurement of SCGB1C1 levels in blood, sputum, nasal lavage fluid, or exhaled breath condensate could potentially identify patients at enhanced risk for upper respiratory infections or progression of allergic airway disease. Dynamic monitoring of SCGB1C1 levels during disease treatment could provide evidence of therapeutic efficacy in modulating the anti-inflammatory SCGB1C1 pathway.

The identification of functional SCGB1C1 polymorphisms associated with nasal polyposis risk raises possibilities for genetic screening to identify individuals at elevated polyp formation risk.[37] Such genetic risk assessment could potentially inform prevention strategies or justify more aggressive anti-inflammatory treatment approaches in genetically susceptible populations. Further validation of SCGB1C1 genetic and serological biomarkers in larger clinical cohorts would be required before clinical implementation.

Limitations of Current Knowledge and Future Research Directions

Incompletely Characterized Receptor Signaling Mechanisms

Despite the well-established effects of SCGB1C1 on regulatory T cell expansion and anti-inflammatory cytokine production, the specific cellular receptors and intracellular signaling cascades mediating these effects remain undefined.[19][20][26][27] Future research must identify the specific receptor or receptors through which SCGB1C1 signals to T cells, dendritic cells, or other target cell populations. The preferential activation of regulatory T cell subsets suggests specificity in receptor recognition rather than non-specific effects, implying the existence of one or more high-affinity SCGB1C1-binding receptors on these cells.

The identification of SCGB1C1 receptor(s) would enable rational therapeutic development including receptor agonists mimicking SCGB1C1's effects and potentially receptor antagonists preventing pathological SCGB1C1-mediated suppression if circumstances warranted immune activation. Crystallographic or cryo-electron microscopic structural analysis of SCGB1C1 in complex with its putative receptor(s) would provide molecular-level understanding of SCGB1C1 signaling, enabling structure-based drug design and optimization of therapeutic efficacy.

Ligand Specificity and Binding Mechanisms for Hydrophobic Molecules

The specific hydrophobic ligands that SCGB1C1 binds in vivo remain incompletely characterized.[28] While structural analysis indicates capacity for binding small hydrophobic molecules including odorants, steroid hormones, and potentially inflammatory lipid mediators, systematic characterization of SCGB1C1 ligand preference through binding assays and biochemical fractionation studies would clarify its physiological roles. The identification of endogenous ligands recognized by SCGB1C1 in different tissue compartments could reveal tissue-specific regulatory mechanisms and enable discovery of therapeutic ligands recapitulating or enhancing SCGB1C1's anti-inflammatory functions.

Mechanistic Understanding of Pathogenic Microorganism Recognition

The mechanisms through which SCGB1C1 recognizes and promotes elimination of pathogenic microorganisms require detailed investigation.[3][22][29][60] Current evidence indicates SCGB1C1 participates in defense against respiratory viruses and bacteria, but whether it directly binds pathogenic surface components, facilitates opsonization by other immune mechanisms, or indirectly promotes pathogen recognition through effects on epithelial or innate immune cell signaling remains unknown. In vitro microbial binding assays with recombinant SCGB1C1 protein and diverse respiratory pathogens could systematically characterize its pathogen recognition specificity.

Conclusion

SCGB1C1 (secretoglobin family 1C member 1) represents a multifunctional secreted protein with specialized roles in mucosal defense, immune regulation, and olfactory function. The protein operates primarily in extracellular compartments at mucosal barrier tissues including the respiratory tract, salivary glands, and olfactory epithelium, where it functions through multiple complementary mechanisms to maintain homeostasis and prevent excessive inflammation. The primary biological functions of SCGB1C1 include recognition and elimination of pathogenic microorganisms from mucosal surfaces with concurrent protection of epithelial cells from pathogenic damage, binding of small hydrophobic ligands including odorants and potentially inflammatory mediators, and promotion of regulatory T cell expansion through production of anti-inflammatory interleukins IL-10 and TGF-β.

The dynamic regulation of SCGB1C1 expression by inflammatory cytokines positions it as an integrator of Th1/Th2 immune balance, with downregulation by the Th1 cytokine interferon-gamma and upregulation by Th2 cytokines including IL-4 and IL-13. Recent experimental evidence conclusively demonstrates that SCGB1C1 suppresses allergic airway inflammation through induction of regulatory T cell populations, providing strong evidence for its therapeutic potential in allergic diseases. The evolutionary conservation of SCGB1C1 across diverse vertebrate taxa extending back approximately 320 million years indicates fundamental biological roles in mucosal defense that have remained important throughout vertebrate evolution.

Future research directions must include identification of specific SCGB1C1 receptors and intracellular signaling pathways, characterization of endogenous ligands bound in different tissue compartments, and elucidation of mechanistic details underlying pathogenic microorganism recognition. The emerging therapeutic applications of SCGB1C1 protein supplementation and extracellular vesicle-mediated SCGB1C1 delivery for treating allergic airway diseases appear promising and warrant further clinical investigation. Integration of SCGB1C1 biomarker measurement into clinical practice for disease risk stratification and therapeutic monitoring represents an achievable goal requiring primarily additional validation studies in appropriately powered clinical cohorts. The protein's multifaceted roles in maintaining mucosal homeostasis, regulating immune tolerance, and defending against pathogens establish SCGB1C1 as a critical component of human innate immunity and a rational target for therapeutic intervention in multiple disease contexts.

Citations

1. https://www.proteinatlas.org/ENSG00000188076-SCGB1C1
2. https://www.alphafold.ebi.ac.uk/entry/Q8TD33
3. https://pmc.ncbi.nlm.nih.gov/articles/PMC4885620/
4. https://www.ncbi.nlm.nih.gov/gene/147199
5. https://amigo.geneontology.org/amigo/gene_product/UniProtKB:Q8TD33
6. https://synapse.patsnap.com/article/what-are-scgb1c1-modulators-and-how-do-they-work
7. https://www.nature.com/articles/s41420-020-00385-w
8. https://pmc.ncbi.nlm.nih.gov/articles/PMC11884772/
9. https://en.wikipedia.org/wiki/Secretoglobin
10. https://onlinelibrary.wiley.com/doi/10.1111/all.15033
11. https://pmc.ncbi.nlm.nih.gov/articles/PMC7252096/
12. https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=147199
13. https://www.genecards.org/cgi-bin/carddisp.pl?gene=SCGB1C1
14. https://pmc.ncbi.nlm.nih.gov/articles/PMC3251818/
15. https://v19.proteinatlas.org/ENSG00000188076-SCGB1C1/tissue
16. https://pubmed.ncbi.nlm.nih.gov/38892470/
17. https://pmc.ncbi.nlm.nih.gov/articles/PMC11173076/
18. https://www.semanticscholar.org/paper/Culture-supernatant-of-adipose-stem-cells-can-via-T-Yu-Park/7df522e05c58e9b8e7c30190666a97a1b70f64d6
19. https://pmc.ncbi.nlm.nih.gov/articles/PMC3706350/
20. https://pubmed.ncbi.nlm.nih.gov/21385388/
21. https://www.proteinatlas.org/ENSG00000188076-SCGB1C1/cancer/breast+cancer
22. https://www.proteinatlas.org/ENSG00000188076-SCGB1C1/tissue/salivary+gland
23. https://cellmolbiol.org/index.php/CMB/article/view/1686
24. https://pmc.ncbi.nlm.nih.gov/articles/PMC4593873/
25. https://pmc.ncbi.nlm.nih.gov/articles/PMC3524297/
26. https://www.tesisenred.net/bitstream/handle/10803/693643/LJG_PhD_THESIS.pdf?sequence=1&isAllowed=y
27. https://pubmed.ncbi.nlm.nih.gov/7835333/
28. https://pmc.ncbi.nlm.nih.gov/articles/PMC7336241/
29. https://pmc.ncbi.nlm.nih.gov/articles/PMC4982115/
30. https://www.proteinatlas.org/ENSG00000188076-SCGB1C1/structure+interaction
31. https://www.uniprot.org/uniprotkb/Q8TD33/entry
32. https://www.uniprot.org/entry/Q7M742
33. https://academic.oup.com/ced/article/48/10/1128/7160873?rss=1
34. https://academic.oup.com/gbe/article/17/3/evaf024/8013461
35. https://pmc.ncbi.nlm.nih.gov/articles/PMC3602116/
36. the Hugo Gene Nomenclature Committee